BioPorto (BIOPOR) - Total Assets
Based on the latest financial reports, BioPorto (BIOPOR) holds total assets worth Dkr93.18 Million DKK (≈ $14.58 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BIOPOR debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
BioPorto - Total Assets Trend (1999–2025)
This chart illustrates how BioPorto's total assets have evolved over time, based on quarterly financial data. See BioPorto shareholders equity for net asset value and shareholders' equity analysis.
BioPorto - Asset Composition Analysis
Current Asset Composition (December 2025)
BioPorto's total assets of Dkr93.18 Million consist of 91.2% current assets and 8.8% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 58.9% |
| Accounts Receivable | Dkr18.52 Million | 19.9% |
| Inventory | Dkr9.25 Million | 9.9% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr138.00K | 0.2% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how BioPorto's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIOPOR company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioPorto's current assets represent 91.2% of total assets in 2025, an increase from 0.0% in 1999.
- Cash Position: Cash and equivalents constituted 58.9% of total assets in 2025, up from 0.2% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 19.9% of total assets.
BioPorto Competitors by Total Assets
Key competitors of BioPorto based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ICON Public Limited Company
F:IJF
|
Germany | €16.51 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Cytogen Inc
KQ:217330
|
Korea | ₩62.24 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
BioPorto - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.25 | 4.12 | 4.03 |
| Quick Ratio | 2.90 | 3.89 | 3.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr58.83 Million | Dkr63.51 Million | Dkr79.85 Million |
BioPorto - Advanced Valuation Insights
This section examines the relationship between BioPorto's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.04 |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | Dkr93.18 Million |
| Market Capitalization | $92.18 Million USD |
Valuation Analysis
Near Book Valuation: The market values BioPorto's assets close to their book value (0.99x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: BioPorto's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BioPorto (1999–2025)
The table below shows the annual total assets of BioPorto from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr93.18 Million ≈ $14.58 Million |
-2.95% |
| 2024-12-31 | Dkr96.01 Million ≈ $15.02 Million |
+6.90% |
| 2023-12-31 | Dkr89.81 Million ≈ $14.05 Million |
-17.33% |
| 2022-12-31 | Dkr108.64 Million ≈ $17.00 Million |
+33.70% |
| 2021-12-31 | Dkr81.25 Million ≈ $12.71 Million |
-42.08% |
| 2020-12-31 | Dkr140.29 Million ≈ $21.95 Million |
+228.68% |
| 2019-12-31 | Dkr42.68 Million ≈ $6.68 Million |
-35.53% |
| 2018-12-31 | Dkr66.20 Million ≈ $10.36 Million |
+0.91% |
| 2017-12-31 | Dkr65.60 Million ≈ $10.26 Million |
+29.55% |
| 2016-12-31 | Dkr50.64 Million ≈ $7.92 Million |
+3.36% |
| 2015-12-31 | Dkr48.99 Million ≈ $7.67 Million |
+31.56% |
| 2014-12-31 | Dkr37.24 Million ≈ $5.83 Million |
-28.17% |
| 2013-12-31 | Dkr51.84 Million ≈ $8.11 Million |
+185.19% |
| 2012-12-31 | Dkr18.18 Million ≈ $2.84 Million |
-14.46% |
| 2011-12-31 | Dkr21.25 Million ≈ $3.33 Million |
+1.33% |
| 2010-12-31 | Dkr20.97 Million ≈ $3.28 Million |
+3.74% |
| 2009-12-31 | Dkr20.22 Million ≈ $3.16 Million |
+5.54% |
| 2008-12-31 | Dkr19.16 Million ≈ $3.00 Million |
-43.49% |
| 2007-12-31 | Dkr33.90 Million ≈ $5.30 Million |
+605.98% |
| 2006-12-31 | Dkr4.80 Million ≈ $751.31K |
-66.80% |
| 2005-12-31 | Dkr14.46 Million ≈ $2.26 Million |
-82.20% |
| 2004-12-31 | Dkr81.27 Million ≈ $12.72 Million |
+0.36% |
| 2003-12-31 | Dkr80.98 Million ≈ $12.67 Million |
+55363.01% |
| 2002-12-31 | Dkr146.00K ≈ $22.84K |
-95.77% |
| 2001-12-31 | Dkr3.45 Million ≈ $540.09K |
-53.71% |
| 2000-12-31 | Dkr7.46 Million ≈ $1.17 Million |
-44.69% |
| 1999-12-31 | Dkr13.48 Million ≈ $2.11 Million |
-- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more